KCT0004609尚未招募未知
PET imaging of patients with elevated PSA using [F-18]Florastamin: Phase I clinical trial
FutureChem0 个研究点目标入组 20 人开始时间: 待定最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 尚未招募
- 发起方
- 入组人数
- 20
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional Study
入排标准
- 年龄范围
- 20(Year) 至 o Limit(—)
- 性别
- Male
入选标准
- •Prostate cancer patient group
- •1. Prostate cancer patient diagnosed histologically
- •- Patient diagnosed with prostate cancer by planning surgery and performing biopsy
- •- Patients with elevated PSA after prostatectomy or radiation therapy
- •- Patients found with clinical progression of prostate cancer
- •2. Subjects who have been fully informed of the purpose and contents of the trial and characteristics of the investigational product before enrolling in the clinical trial by subinvestigators and signed the consent form by themselves, their guardian or a legal representative.
- •3. Male patient aged 19 or older
- •4. ECOG _ Performance scale =2
- •5. Expect at least 12 months of survival
- •6. Those who meet the following conditions in blood tests, renal and liver function tests
- •- Platelet count (PLT)> 50,000/µL
- •- BUN and serum creatinine <1.5 x upper limit of normal (ULN)
- •- AST and ALT <2.5 x upper limit of normal (ULN)
- •- Left ventricle ejection fraction > 60% if there is a history of heart disease
排除标准
- •1. Those who were judged as difficult to conduct the clinical trial due to serious medical conditions by the investigator
- •2. Those who were judged to have a mental illness that makes it difficult to obtain positron emission tomography (PET) by the investigator
- •3. Participant in another clinical trial that may affect [F-18]Florastamin PET image acquisition from enrolling in the clinical trial to the end of the clinical trial or may affect the safety assessment following intravenous injection of [F-18]Florastamin (e.g., a subject from a cohort clinical trial that is conducted with only a follow-up observation without receiving the investigational product from enrollment until the end of the clinical trial can participate.)
- •4. Those who were judged as inappropriate to participate in the clinical trial by the investigator
- •5. Vulnerable subjects (investigator self or one’s family who participated in the trial, investigator or students of investigator who participated in the study, or families of the subjects)
研究者
相似试验
进行中(未招募)
1 期
Interest of PET-PSMA Imaging potentialised by androgen blockade in localized prostatic adenocarcinoma in relapse or reccurent diseaseEUCTR2019-003346-32-FRCentre Léon Bérard52
已完成
不适用
68Ga-PSMA-PET/CT imaging for locally advanced, recurrent and metastatic adenoid cystic carcinoma or salivary duct carcinomaAdenoid cystic carcinomaNL-OMON44299Radboud Universitair Medisch Centrum25
进行中(未招募)
1 期
PSMA-PET scan for incurable or metastatic salivary gland cancerEUCTR2017-002093-40-NLRadboudumc25
招募中
不适用
Evaluation of new PET tracer, [F-18]Florastamin for diagnosing prostate cancer: Phase I clinical trialKCT0004817FutureChem10
招募中
早期 1 期
68Ga-PSFA PET Imaging in Patients With PSMA/FAP Positive DiseasePSMAPositron-Emission TomographyFAPNCT06387381First Affiliated Hospital of Chongqing Medical University30
